Compare · DNA vs GILD
DNA vs GILD
Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $162.43B, about 310.0x DNA ($523.9M).
- Over the past year, DNA is up 38.8% and GILD is up 27.5% - DNA leads by 11.3 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 11 for DNA).
- GILD has more recent analyst coverage (25 ratings vs 17 for DNA).
- Company
- Ginkgo Bioworks Holdings Inc.
- Gilead Sciences Inc.
- Price
- $9.69+14.67%
- $131.63+0.60%
- Market cap
- $523.9M
- $162.43B
- 1M return
- +42.92%
- -6.18%
- 1Y return
- +38.83%
- +27.50%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 11
- 12
- Recent ratings
- 17
- 25
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest DNA
- Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
- SEC Form DEFA14A filed by Ginkgo Bioworks Holdings Inc.
- SEC Form DEF 14A filed by Ginkgo Bioworks Holdings Inc.
- SEC Form 4 filed by Coen Steven P.
- SEC Form 4 filed by Coen Steven P.
- SEC Form 4 filed by Canton Barry
- SEC Form 4 filed by Shetty Reshma P.
- SEC Form 4 filed by Shetty Reshma P.
- SEC Form 4 filed by Canton Barry
- SEC Form 4 filed by Kelly Jason R
Latest GILD
- Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
- Chairman & CEO O'Day Daniel Patrick sold $1,291,608 worth of shares (10,000 units at $129.16) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 632,567 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits, Other Events
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE